US › Healthcare

Protalix Biotherapeutics Inc (PLX)

US · Healthcare · Biotechnology

$2.37+2.16%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$33.8M

Revenue YoY

+233.7%

Net profit

$18.3M

Profit YoY

+606.1%

EPS

$0.22

EPS estimate

$-0.01

Net margin

54.3%

EPS came in at 0.22 against a street estimate of -0.01 — a beat of 2300.0%.

Key statistics

Market cap

$191.0M

P/E

12.5

Forward P/E

12.2

P/B

2.84

Book value

$0.83

EPS (TTM)

$0.19

52-week high

$3.19

52-week low

$1.42

50-day MA

$2.21

200-day MA

$2.22

Beta

-0.00

Analyst view

Analysts rate Protalix Biotherapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $11.00.

Shareholding

Insiders

3.88%

Institutions

20.97%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Protalix Biotherapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.